Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
115.86 USD | +0.53% | -1.68% | +6.27% |
12/09 | Merck Says Health Canada Approved Keytruda as Treatment for Hard-to-Treat Solid Tumors | MT |
11/09 | Merck: positive results for HPV vaccine | CF |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Net Income | 9.84B | 7.07B | 13.05B | 14.52B | 365M | |||||
Depreciation & Amortization - CF | 1.42B | 1.46B | 1.49B | 1.7B | 1.69B | |||||
Amortization of Goodwill and Intangible Assets - (CF) | 2B | 1.9B | 1.64B | 2.08B | 2.04B | |||||
Depreciation & Amortization, Total | 3.42B | 3.36B | 3.12B | 3.79B | 3.73B | |||||
(Gain) Loss From Sale Of Asset | - | - | - | - | - | |||||
Asset Writedown & Restructuring Costs | 1.27B | 1.99B | 393M | 1.87B | 932M | |||||
(Income) Loss On Equity Investments - (CF) | - | - | -1.94B | 1.42B | -340M | |||||
Stock-Based Compensation (CF) | 417M | 475M | 479M | 541M | 645M | |||||
Net Cash From Discontinued Operations | - | - | 987M | - | - | |||||
Other Operating Activities, Total | 555M | 1.96B | 1.86B | -260M | 9.88B | |||||
Change In Accounts Receivable | 294M | -1B | -2.03B | -644M | -1.15B | |||||
Change In Inventories | -508M | -855M | -674M | -161M | -816M | |||||
Change In Accounts Payable | 399M | 724M | 405M | -289M | -380M | |||||
Change In Income Taxes | -2.36B | 560M | -540M | 380M | 214M | |||||
Change in Other Net Operating Assets | 107M | -4.02B | -997M | -2.07B | -75M | |||||
Cash from Operations | 13.44B | 10.25B | 14.11B | 19.1B | 13.01B | |||||
Capital Expenditure | -3.47B | -4.68B | -4.45B | -4.39B | -3.86B | |||||
Cash Acquisitions | -4.95B | -6.61B | -12.91B | -121M | -12.03B | |||||
Divestitures | - | - | - | - | - | |||||
Sale (Purchase) of Intangible assets | - | - | - | - | - | |||||
Investment in Marketable and Equity Securities, Total | 5.42B | 1.72B | 1.02B | -483M | 1.85B | |||||
Other Investing Activities, Total | 378M | 130M | -225M | 32M | -36M | |||||
Cash from Investing | -2.63B | -9.44B | -16.56B | -4.96B | -14.08B | |||||
Short Term Debt Issued, Total | - | 2.55B | - | - | - | |||||
Long-Term Debt Issued, Total | 4.96B | 4.42B | 7.94B | - | 5.94B | |||||
Total Debt Issued | 4.96B | 6.97B | 7.94B | - | 5.94B | |||||
Short Term Debt Repaid, Total | -3.71B | - | -3.99B | - | - | |||||
Long-Term Debt Repaid, Total | - | -1.96B | -2.32B | -2.25B | -1.76B | |||||
Total Debt Repaid | -3.71B | -1.96B | -6.3B | -2.25B | -1.76B | |||||
Issuance of Common Stock | 361M | 89M | 202M | 384M | 125M | |||||
Repurchase of Common Stock | -4.78B | -1.28B | -840M | - | -1.35B | |||||
Common Dividends Paid | -5.7B | -6.22B | -6.61B | -7.01B | -7.44B | |||||
Common & Preferred Stock Dividends Paid | -5.7B | -6.22B | -6.61B | -7.01B | -7.44B | |||||
Other Financing Activities, Total | 5M | -436M | 8.21B | -240M | -328M | |||||
Cash from Financing | -8.86B | -2.83B | 2.59B | -9.12B | -4.81B | |||||
Foreign Exchange Rate Adjustments | 17M | 253M | -133M | -410M | 23M | |||||
Net Change in Cash | 1.97B | -1.77B | 14M | 4.61B | -5.86B | |||||
Supplemental Items | ||||||||||
Cash Interest Paid | 841M | 822M | 779M | 937M | 1.1B | |||||
Cash Income Tax Paid (Refund) | 4.5B | 2.7B | 2.4B | 3.2B | 4.34B | |||||
Levered Free Cash Flow | 10.68B | 7.49B | 6.67B | 12.69B | 9.26B | |||||
Unlevered Free Cash Flow | 11.24B | 8.01B | 7.17B | 13.29B | 9.98B | |||||
Change In Net Working Capital | -1.45B | 445M | 1.89B | -496M | 520M | |||||
Net Debt Issued / Repaid | 1.25B | 5.01B | 1.63B | -2.25B | 4.18B |